Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
First participant receives Evategrel in CureGene’s trial
CureGene Pharmaceutical has dosed the first participant in its pivotal clinical trial of Evategrel (CG-0255), a next-generation antiplatelet therapy, in …
-
Imperative Care reports SYMPHONY-PE trial data for pulmonary embolism
Imperative Care has reported results from a post-hoc analysis of the SYMPHONY-PE trial, assessing the role of early mechanical thrombectomy …
-
Japan approves Sanofi’s Sarclisa combo for MM treatment
Sanofi has received approval from Japan's Ministry of Health, Labour and Welfare for its subcutaneous (SC) formulation of Sarclisa (isatuximab) …
-
Charles River collaborates with Lilly TuneLab platform
Charles River Laboratories International has entered a collaboration with Eli Lilly and Company’s artificial intelligence / machine learning (AI/ML)-focused drug …
-
MAIA activates new site for THIO-101 Phase II trial
MAIA Biotechnology has activated a new US site, the Winship Cancer Institute of Emory University, and opened patient enrolment for …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Biogen to acquire RayThera for up to $1bn
Biogen has entered a definitive agreement to acquire RayThera, a biotechnology company specialising in small-molecule therapies for immunology, for up …
-
Global semiconductors hiring slows after Q1 surge: What this means for your sector
For company leaders, detailed hiring and workforce data is an early warning system for performance. It shows where skills are …
-
AngioDynamics secures FDA approval for RELIEF study of NanoKnife
AngioDynamics has received approval from the US Food and Drug Administration (FDA) for an investigational device exemption application to begin …
-
First patient dosed in Deciphera’s Phase III INTREPID study
Deciphera Pharmaceuticals has dosed the first patient in its global pivotal Phase III INTREPID study, evaluating sapablursen for the treatment …
-
LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs
LG AI Research and D&D Pharmatech have entered an agreement to collaborate on the development of next-generation oral peptide drugs, …
-
Alpha Cognition begins enrolment in RESOLVE Phase IV trial for Zunveyl
Alpha Cognition has started enrolling patients in its RESOLVE Phase IV post-marketing study, which is evaluating the tolerability and real-world …
-
Altaris to acquire Simulations Plus in $375m all-cash deal
Simulations Plus has entered a definitive agreement to be purchased by affiliates of Altaris in an all-cash transaction valued at …
-
Distalmotion secures second FDA gynaecology clearance for DEXTER system
Swiss medical device company Distalmotion has secured the US Food and Drug Administration (FDA) 510(k) clearance for its DEXTER robotic …
-
Takeda reports pivotal data from FirstLight and RadiantLight trials
Takeda has reported pivotal results from its Phase III FirstLight and RadiantLight studies of oveporexton (TAK-861), an oral orexin receptor …
-
FDA approves Bayer’s Ambelvist contrast agent
The US Food and Drug Administration (FDA) has approved Bayer’s Ambelvist (gadoquatrane), a macrocyclic gadolinium-based contrast agent (mGBCA), for use …
